Clinical Trials on Fibrosis Lung in France

Total 6192 results

Fondation Hôpital Saint-Joseph

Not yet recruiting

Influence of Diabetic Control on the Degree of Liver Fibrosis Assessed by Non-invasive Scores in Patients Followed in Diabetology (DIAFIB)

Diabete Type 2

France
Novartis Pharmaceuticals

Completed

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis (EAGER)

Cystic Fibrosis

United States, Germany, United Kingdom, Colombia, Spain, France, Netherlands, Israel, Canada, Italy, Chile, Australia, Hungary, Mexico
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis | Pancreatic Exocrine Insufficiency

United States
University Hospital, Angers

Completed

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study) (IMPROVE)

NAFLD | Liver Fibrosis | Alcohol-Related Disorder

France
Nantes University Hospital

Completed

Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation (Astronef)

Renal Transplant

France
French National Agency for Research on AIDS and...

Terminated

Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C

Hepatitis C, Chronic | Liver Fibrosis

France
Universitaire Ziekenhuizen KU Leuven
KU Leuven; Vertex Pharmaceuticals Incorporated; University of Lisbon

Withdrawn

Organoid Study R334W

Cystic Fibrosis

Spain, Italy, France, Belgium, Portugal
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Fondation Ildys
University Hospital, Brest; Vaincre la Mucoviscidose

Completed

Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO) (PerineoMuco)

Cystic Fibrosis

France
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Centre Hospitalier Universitaire, Amiens

Recruiting

MILTA vs Placebo Use Comparison for the Management of Pain Related to Perineal Scars Following Delivery (MILTADoIP)

Pain | Treatment | Episiotomy | Delivery Complication | Perineal Scars

France
University Hospital, Caen

Completed

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. (AutoSop-Foie)

Cirrhosis

France
Assistance Publique - Hôpitaux de Paris

Terminated

Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure (NORFLOCIR)

Cirrhosis

France
Assistance Publique - Hôpitaux de Paris

Completed

Clinical Trial of Pentoxifylline in Patient With Cirrhosis (PENTOCIR)

Liver Failure | Cirrhosis

France
Pharmaxis
ethica Clinical Research Inc.; Europe: KasaConsult bvba, Hoegaarden, Belgium; Argentina: Resolution Latin America; Buenos Aires, Argentina

Completed

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Canada, Argentina, Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
Hospices Civils de Lyon

Recruiting

Study of microRNAs in a Decompensated Cirrhosis (EmiC)

Cirrhosis | Acute Decompensation

France
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis

United States, Hungary, Israel, South Africa, Spain
Nantes University Hospital

Recruiting

Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus (L-FibroT2DM)

Diabetes Mellitus, Type 2 | NAFLD | NASH

France
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Aradigm Corporation
Grifols Therapeutics LLC

Completed

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

Non Cystic Fibrosis Bronchiectasis

United States, Italy, Poland, United Kingdom, France, Spain, Israel, Romania, Korea, Republic of, Australia, Canada, New Zealand, Hungary, Georgia, Former Serbia and Montenegro, Peru
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Hospices Civils de Lyon

Completed

HPV Vaccination in Women With Cystic Fibrosis (VACCIN-HPV-MUC)

Human Papillomavirus Infection

France
Poitiers University Hospital

Completed

A Comparison of Balloon Catheter Versus Ocytocin for Cervical Ripening on Scarred Uterus With Unfavorable Cervix

Scarred Uterus

France
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
University Hospital, Rouen

Completed

Influence of Probiotics Administration Before Liver Resection in Liver Disease (LIPROCES)

Liver Cirrhosis | Hepatocellular Carcinoma | Liver Fibrosis | Permeability; Increased

France
Hospices Civils de Lyon

Completed

Monocytic Expression of HLA-DR After Liver Transplantation (EdMonHG)

Liver Diseases | Liver Transplantation | Cirrhosis, Liver

France
Centre Hospitalier Universitaire, Amiens

Terminated

Evaluation of Lactoferrin, Procalcitonin and Aution® Urine Dipsticks for the Diagnosis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients

Liver Cirrhosis

France
University Hospital, Angers

Not yet recruiting

Characterization of the Immunometabolic Signature in Long COVID-19. (LoCo-ImMet)

Long COVID

France
Seattle Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center

Completed

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH)

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
PTC Therapeutics

Terminated

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Cystic Fibrosis

United States, Spain, France, Belgium, United Kingdom, Australia, Brazil, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Argentina, Greece
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
University Hospital, Brest

Not yet recruiting

Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation (CFTR-EP)

Cystic Fibrosis | Congenital Bilateral Absence of Vas Deferens | Sterility, Male

France
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Study of Ataluren (PTC124™) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, United Kingdom, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden
AbbVie

Completed

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Cystic Fibrosis

United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
Celtaxsys, Inc.

Completed

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Cystic Fibrosis

United States, United Kingdom, Canada, Belgium, France, Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada

Clinical Trials on Fibrosis Lung in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations